Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
0.839
-0.114 (-11.96%)
At close: Dec 5, 2025, 4:00 PM EST
0.850
+0.011 (1.31%)
After-hours: Dec 5, 2025, 7:38 PM EST

Liminatus Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
2.250.651.060.860.2
Research & Development
-02.693.761.853.8
Operating Expenses
2.253.334.822.714
Operating Income
-2.25-3.33-4.82-2.71-4
Interest Expense
-0.3-0.34-0.18-0.22-1.61
Interest & Investment Income
0.120.120.01--
Pretax Income
-2.27-3.55-4.98-2.93-5.61
Net Income
-2.27-3.55-4.98-2.93-5.61
Net Income to Common
-2.27-3.55-4.98-2.93-5.61
Shares Outstanding (Basic)
11611210236-
Shares Outstanding (Diluted)
11611210236-
Shares Change (YoY)
181.69%9.49%188.25%--
EPS (Basic)
-0.02-0.03-0.05-0.08-
EPS (Diluted)
-0.02-0.03-0.05-0.08-
EBITDA
----2.71-4
D&A For EBITDA
---00
EBIT
-2.25-3.33-4.82-2.71-4
Source: S&P Capital IQ. Standard template. Financial Sources.